Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 1/20 | 0.32 |
| ▸ | CDC25B | P30305 | 1/20 | 0.32 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.30 |
| ▸ | UCHL3 | P15374 | 1/20 | 0.30 |
| ▸ | ECE1 | P42892 | 1/20 | 0.30 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16201624 | 0.80 | CDC25A (0.32) | CDC25ACDC25B | |
| SCHEMBL16201630 | 0.73 | — | — | |
| SCHEMBL3413343 | 0.70 | CDC25A (0.37) | CDC25ACDC25B | |
| SCHEMBL20368670 | 0.66 | — | — | |
| SCHEMBL11910532 | 0.65 | — | — | |
| SCHEMBL7158411 | 0.65 | — | — | |
| SCHEMBL7237677 | 0.64 | CDC25A (0.31) | CDC25ACDC25B | |
| SCHEMBL1690050 | 0.64 | UCHL1 (0.35) | UCHL1UCHL3ECE1MUS81 | |
| SCHEMBL525595 | 0.62 | — | — | |
| SCHEMBL5590100 | 0.60 | CDC25A (0.32) | CDC25ACDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9345905-B2 | Heterocyclic amides compounds which are HDAC6 inhibitors and used as anti-tumoral agents | NANJING ALLGEN PHARMA CO. LTD. (CN) | 2016-05-24 | — | — | US | disclosed |
| US-20140322229-A1 | HETEROCYCLIC AMIDES COMPOUNDS WHICH ARE HDAC6 INHIBITORS AND USED AS ANTI-TUMORAL AGENTS | BETA PHARMA CANADA INC. (CA) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140322229-A1 | HETEROCYCLIC AMIDES COMPOUNDS WHICH ARE HDAC6 INHIBITORS AND USED AS ANTI-TUMORAL AGENTS | HDAC6, HDAC1, HDAC7 | CDC25A 719/4885CDC25B 773/4885UCHL1 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.